AUCTORES
Globalize your Research
Research Article | DOI: https://doi.org/10.31579/2690-1897/153
North Manchester General Hospital, Department of Urology, Manchester, M8 5RB. United Kingdom.
*Corresponding Author: Anthony Kodzo-Grey Venyo. North Manchester General Hospital, Department of Urology, Manchester, M8 5RB. United Kingdom.
Citation: Anthony Kodzo-Grey Venyo, (2023), Invasive Group A Streptococcus: A Review and Update, J, Surgical Case Reports and Images 6(4); DOI:10.31579/2690-1897/153
Copyright: © 2023, Anthony Kodzo-Grey Venyo. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received: 04 April 2023 | Accepted: 25 April 2023 | Published: 08 May 2023
Keywords: streptococcus pyogenes; invasive infections; group a streptococcus; invasive group a streptococcus (igas); bacteria; streptococci; public health; long-term care; infection control; disease outbreaks; whole-genome sequencing
Group A Streptococcus (GAS), or Streptococcus pyogenes, is the leading bacterial cause of tonsillopharyngitis in adults and children worldwide. GAS is one of the few causes of tonsillopharyngitis or pharyngitis for which antibiotic treatment is recommended. The incidence of group A Streptococcus (GAS) invasive infection has been increasing worldwide, and there is no obvious explanation for this phenomenon.
Recurrent GAS infections may trigger autoimmune diseases such as acute poststreptococcal glomerulonephritis, acute rheumatic fever, and rheumatic heart disease. Combined, these diseases account for over half a million deaths per year globally.
While GAS remains sensitive to all penicillins and cephalosporins, rising resistance to other antibiotics used in disease treatment is an increasing worldwide concern. Several GAS vaccine formulations that elicit protective immunity in animal models have shown promise in nonhuman primate and early-stage human trials. The development of a safe and efficacious commercial human vaccine for the prophylaxis of GAS disease remains a high priority.
Group A streptococcus (GAS) e.g., Streptococcus pyogenes is an aerobic gram-positive coccus that is a common cause of acute bacterial pharyngitis and other cutaneous and invasive infections in children for which antibiotic is recommended [1, 2]. Invasive GAS infections are defined as bacteraemia, pneumonia, osteomyelitis, septic arthritis, or any other infection associated with the isolation of GAS from a normally sterile body site [2].
Invasive infections also include necrotizing fasciitis and spontaneous gangrenous myositis.
Group A Streptococcus (GAS) can cause symptomatic infection or can colonize the oropharynx.
Distinguishing among these states is important because only patients with symptomatic GAS infection require treatment. The ensuing article on Invasive Group A Streptococcus infections had been divided into two parts: [A] Overview which has discussed general overview of Streptococcus and (B) which contains detailed review and update summations on various aspects of Invasive Group A Streptococcus infections.
In this review and update we have focussed on (A) an overview of Streptococcus infection generally and (B) we have focussed on the general aspects of GAS invasive infection, as well as on certain entities, such as bacterial pharyngitis. We have reviewed all therapeutic avenues, old and new, that are relevant to the treatment of GAS infections.
Internet data bases were searched including: Google; Google Scholar; and PUBMED. The search words that were used included: Streptococcus; Streptococcus pyogenes; Group A Streptococcus, invasive Group A Streptococcus (iGAS), two hundred and one (201) references were identified which were used to write the review and update of the literature on Streptococcus infections and the differential diagnoses of various conditions that tend to simulate Streptococcus infections. The article has been divided into two parts (A) Overview of Streptococcus infections and (B) Detailed discussions related to various aspects of Invasive Group A Streptococcus.
[A] Overview
Definition / general statements [13]
Terminology [13]
Streptococci tend to be grouped broadly according to the haemolytic pattern of the organism that is seen upon blood agar examination into alpha, beta and other subtypes of Streptococcus as follows:[13]
Aetiology
With regard to the aetiology of or causative Streptococcal organisms that tend to be found as causative Streptococcus organisms in infections of various parts of the body, the following summations had been made: [13]
Laboratory tests
The following laboratory tests tend to be undertaken in various scenarios related to Streptococcus infections: [13]
Treatment
Some of the treatment options that had been utilized in some types of Streptococcus infections had been summarized as follows: [13]
Gross macroscopy description
The macroscopy gross examination findings that tend to be found in Streptococcus infections had been summarized to include the following: [13]
Molecular / cytogenetics description [13]
Differential diagnosis
With regard to the differential diagnosis of Streptococcus infections, the following iterations had been made: [13]
[B] Detailed Review and Update Related to Various Aspects of Invasive Group A Streptococcus Infections
Incidence
GAS bacteraemia usually occurs secondary to a primary site of infection, most commonly in the skin and soft tissues [20-22]. The estimated incidence of GAS bacteraemia and/or invasive infection in children is 1 to 3 cases per 100,000 per year [23-26] The incidence is greatest in children <1>
Among hospitalized patients, invasive GAS infection accounts for approximately 0.3 to 0.9 percent of paediatric hospital admissions [27,28].
● United States – Invasive GAS attack rates have been relatively stable in the United States since the mid-1990s. Approximately 100 to 200 paediatric cases were reported to the Active Bacterial Core (ABC) surveillance at the Centres for Disease Control and Prevention (CDC) each year from 2015 through 2019 [25,26,29-32]. There were only 74 cases reported in 2020, likely due to the impact of social distancing and other infection control measures during the height of the COVID-19 pandemic [26]. Similarly, in a report from Texas Children's Hospital, there were considerably fewer hospital admissions for invasive GAS infections in 2020 compared with previous years, though the rate increased again by 2022 [28]. In December of 2022, the CDC issued a health advisory regarding an increase in the number of cases of paediatric invasive GAS infection reported to the ABC surveillance program in November through early December [33]. The CDC is investigating these reports. Based on preliminary data, the increase likely reflects that rates of invasive GAS infection appear to have returned to levels like those seen in pre-pandemic years [34].
● Europe – Several European countries have reported an increase in the number of invasive GAS infections among children <10>
Other European countries, including France, Ireland, the Netherlands, and Sweden have reported similar increases in rates of invasive GAS infection, particularly among children <10>3-fold increase in reported cases of scarlet fever. The increase may reflect an early GAS season coinciding with an increase in circulating respiratory viruses. There have been no observed increases in antibiotic resistance among isolated GAS strains. Enhanced surveillance activities have been implemented in the affected areas and public health organizations are emphasizing the importance of early recognition of GAS infections, including scarlet fever, and prompt treatment.
Epidemiology of Group A streptococcal bacterial pharyngitis.
GAS is the most common cause of bacterial pharyngitis in children and adolescents. It accounts for 15 to 30 percent of all cases of pharyngitis in children between the ages of 5 and 15 years [37-40].
In temperate climates, the incidence of GAS pharyngitis peaks during the winter and early spring [41]. During these seasons, as many as 35 to 40 percent of cases of pharyngitis in children and adolescents are caused by GAS.
GAS pharyngitis is most common in school-age children but may occur in younger children, especially if they have contact with school-age children [41-42]. In a meta-analysis, the pooled prevalence of GAS among children (<18>
Historical perspective
GAS was first described in 1874 by Billroth, who demonstrated its presence in wound infections and erysipelas. Pasteur identified GAS as the cause of puerperal sepsis in 1879. In 1884, Rosenbach gave it the name Streptococcus pyogenes. Lancefield made a major contribution in the field of epidemiology in 1933, when she classified β-haemolytic streptococci in different groups [43].
Throughout history, GAS has been responsible for major epidemics with catastrophic consequences [22]. With the advent of better hygiene, penicillin and modern medicine, there was a striking drop in the incidence of severe GAS infections [44,45]. Now, for unknown reasons, there has been a surge of severe, life-threatening infections, notably in developed countries [43].
In Sweden, the number of cases of GAS bacteraemia per 100 000 population jumped from 1.8 in 1987 to 2.4 in 1989 [46]. In Arizona, a study conducted between January 1987 and March 1990 showed an annual age adjusted incidence of GAS invasive infections of 4.3 per 100 000 population. But the infection rate was much higher among native Americans (46 per 100 000) [47]. In 1992, the annual incidences in Ontario of invasive GAS infections and STSS were 1.15 and 0.19 per 100 000 population respectively [22]. In 1994, a definite increase in the number of cases of necrotizing fasciitis was noted compared with previous years [43].
Since end of year 2022, there have been more cases of GAS in the lower respiratory tract, including cases of empyema, and more cases of scarlet fever, which is a notifiable disease [48].
The pathogen and pathophysiology
GAS is a gram-positive coccus that produces and has numerous constituents, somatic and extracellular, capable of an important role in the pathogenesis of the invasive infection. First, certain proteins are produced and expressed at the surface of the bacterium, notably the M protein, which is a major virulence factor. This antigen has the ability to decrease phagocytosis by polymorphonuclear leukocytes and plays an important role in initiating the streptococcal diseases. There are about 80 different types of M protein. Not all group A streptococci carry the M protein, some are called non-typable and are considered to be less virulent. Another important surface antigen is called the serum opacity factor (SOF), so named because of its ability to opacify horse serum. For more precise typing and identification purposes, another protein called T protein has been identified by Griffith [49]. Apart from its epidemiologic importance, this protein has no virulence potential.
Extracellular toxins are produced by GAS and represent essential mediators of the bacterial virulence. Among them are the streptococcal pyrogenic exotoxins (SPEs). Three different types of SPEs have been characterized and named A, B and C. These toxins have been shown, experimentally, to induce cytotoxicity and to provoke symptoms comparable to those seen in the staphylococcal toxic shock syndrome. SPE-A and the staphylococcal toxic shock syndrome toxin-1 (TSST-1) have a similar molecular structure [50].
The pathophysiology of severe GAS infections is not fully understood, but SPEs are playing a key role as superantigens (bacterial products, mainly from gram-positive bacteria that have the ability to massively stimulate nonspecific T-cell proliferation) [2,51,52]. The T-cell proliferation, once activated, enhances the production of cytokines. Large production of tumour necrosis factor (TNF) and interleukins (1β and 6) mediate fever, shock, tissue injury and the spectacular inflammatory process seen in STSS. SPEs can trigger such a response because of their ability to cross-link the major histocompatibility complex (MHC) molecule on antigen-presenting cells, with the variable region of the T-cell receptor β chain [43,51]. Compared with conventional antigens, superantigens are unique in that they can activate a T cell without being previously processed by an antigen-presenting cell. Besides, specific interaction between conventional antigens and T cells is governed by the 5 variable regions of the T-cell receptor (Ja, Va, Jb, Db, Vb), whereas the coupling of superantigens with T cells is primarily under the control of only the Vb region, with little contribution from the other regions of the T-cell receptor. Thus, a conventional antigen usually activates less than 0.01% of all T cells; in contrast, a superantigen can stimulate between 5% and 40% of all T cells [51].
Manifestations and clinical Presentations of invasive Group A Streptococcus (iGAS).
Group A Streptococcus (GAS) is carried as a commensal in the nasopharynx of 5 – 15% of the population [52] and can cause pharyngitis and scarlet fever. iGAS is a rare but serious complication of infection with GAS and occurs when the bacteria infect a site that is usually sterile such as the blood, joints or lungs [48].
Clinical presentations of GAS may include a simple sore throat, tonsillitis or scarlet fever. Scarlet fever, which is a notifiable disease, presents in a typical way. The initial symptoms are non-specific (sore throat, headache, fever) and a rash will develop within two days. The rash is rough, described as like sandpaper, and it starts on the torso and spreads from there, but usually spares the palms and the soles. Pastia’s lines may be seen – these are deep red lines where the rash is accentuated in the flexures [52,53].
Other features include a strawberry tongue – the tongue has a white coating which peels off after a few days, leaving the tongue looking red and swollen – enlarged cervical lymph nodes, general malaise, peeling skin on the fingertips and toes and a flushed face with pallor around the mouth [47,52, 53].
GAS is the most common cause of bacterial pharyngitis in children and adolescents. It accounts for 15 to 30 percent of all cases of pharyngitis in children between the ages of 5 and 15 years [37-40].
In temperate climates, the incidence of GAS pharyngitis peaks during the winter and early spring [41]. During these seasons, as many as 35 to 40 percent of cases of pharyngitis in children and adolescents are caused by GAS.
GAS pharyngitis is most common in school-age children but may occur in younger children, especially if they have contact with school-age children [41-42]. In a meta-analysis, the pooled prevalence of GAS among children (<18>
Children ≥3 years — In children ≥3 years, GAS pharyngitis typically has an abrupt onset. Fever, headache, abdominal pain, nausea, and vomiting may accompany the sore throat, which can lead to poor oral intake [39,54,55]. Additional features may include exudative tonsillopharyngitis, with enlarged erythematous tonsils, enlarged tender anterior cervical lymph nodes, palatal petechiae, inflamed uvula (uvulitis), and scarlatiniform rash (erythematous, finely papular rash which characteristically starts in the groin and axilla and then spreads to the trunk and extremities, followed by desquamation) [39,54,56]. Viral features (eg, rhinorrhoea, conjunctivitis, cough, hoarseness, anterior stomatitis, discrete ulcerative lesions or vesicles, diarrhoea) are usually absent. Symptoms usually resolve spontaneously in three to five days.
Children <3>
Infants <1>
Complications — Although most cases of GAS pharyngitis resolve without complications, serious nonsuppurative and suppurative complications may occur.
•Nonsuppurative complications of GAS pharyngitis include Acute rheumatic fever (ARF)
•Poststreptococcal reactive arthritis (PSRA)
•Acute rheumatic fever
•Poststreptococcal glomerulonephritis
•Paediatric autoimmune neuropsychiatric disorders associated with streptococcus (PANDAS)
•Suppurative complications of GAS pharyngitis
•Necrotizing fasciitis
•Bacteraemia
•Peritonsillar cellulitis or abscess
•Otitis media
•Sinusitis
Importance of accurate diagnosis — GAS is the most common cause of bacterial pharyngitis that benefits from antimicrobial therapy. Depending upon the season, as many as 35 to 40 percent of cases of pharyngitis in children and adolescents are caused by GAS. Timely treatment of GAS in children and adolescents is necessary to:
•Prevent suppurative complications and acute rheumatic fever (ARF)
•Prevent disease transmission, particularly if the patient is a contact of someone with a history of ARF [54]
•Reduce duration and severity of symptoms
Microbiologic confirmation of GAS in the pharynx before initiation of antibiotic therapy helps to prevent unnecessary prescription of antibiotics to children with viral pharyngitis (most children with pharyngitis) [59].
Diagnosis
Diagnostic criteria — The diagnosis of GAS pharyngitis is supported by a positive microbiologic test (throat culture, rapid antigen detection test [RADT], or molecular point-of-care test [POC] for GAS) in a patient with symptoms of GAS pharyngitis and absence of signs and symptoms of viral infections (e.g., rhinorrhoea, conjunctivitis, cough, hoarseness, anterior stomatitis, discrete ulcerative lesions or vesicles, diarrhoea). However, the presence of isolated viral features (e.g., cough, rhinorrhoea) does not preclude a diagnosis of GAS pharyngitis [59].
Although a positive test supports the diagnosis of GAS, between 5 and 21 percent of children between 3 and 15 years of age are pharyngeal carriers of GAS [4,9,11,60,61]. Neither throat culture, RADT, nor molecular POC test for GAS can differentiate patients with acute GAS pharyngitis from GAS carriage with intercurrent viral illness [39]. Such patients may fail to respond to appropriate therapy for GAS infection.
Approach to testing — The approach to testing for GAS pharyngitis is generally consistent with that of the Infectious Diseases Society of America, the American Heart Association, American Academy of Paediatrics, and other professional groups [39,54,60,61].
Whom to test — Microbiologic testing is suggested for GAS in children and adolescents with [39,54,60]:
1. Evidence of acute tonsillopharyngitis (erythema, oedema, and/or exudates) or scarlatiniform rash on physical examination and absence of multiple signs and symptoms of viral infections (e.g., rhinorrhoea, conjunctivitis, cough, hoarseness, anterior stomatitis, discrete ulcerative lesions or vesicles, diarrhoea).
2. Exposure to an individual with GAS at home or school or a high prevalence of GAS infections in the community and symptoms of GAS, including:
i. For children ≥3 years – Pharyngitis, fever, headache, abdominal pain, enlarged tender anterior cervical lymph nodes, palatal petechiae [39,54,55].
ii. For children <3>
No single sign or symptom reliably identifies GAS pharyngitis in children with sore throats [39,54,56]. In a meta-analysis, although individual findings (e.g., scarlatiniform rash, palatal petechiae, tonsillar enlargement, tender cervical lymphadenopathy) increased the probability of GAS pharyngitis to >50 percent, they could not be used for definitive diagnosis [56].
Similarly, clinical scoring systems for GAS that consist of various constellations of clinical findings and epidemiologic features [62-65] are insufficiently sensitive or specific to eliminate the need for microbiologic testing in children and adolescents with suspected GAS [39,56, 66-68]
3. Suspected acute rheumatic fever (ARF) or poststreptococcal glomerulonephritis.
To prevent identification of GAS carriers with viral respiratory infection, microbiologic testing for GAS should be avoided in children and adolescents with multiple manifestations strongly suggestive of viral illness (e.g., rhinorrhoea, conjunctivitis, cough, hoarseness, anterior stomatitis, discrete ulcerative lesions or vesicles, diarrhoea) [39,60,69,70]. Nonetheless, in a child with fever, exudative pharyngitis, and isolated rhinorrhoea or cough, microbiologic testing may be warranted. Although viral features are usually absent in children with GAS pharyngitis, the presence of isolated viral features does not preclude a diagnosis of GAS pharyngitis. In a retrospective study of >60,000 children and adolescents (age 3 to 21 years) who were tested for GAS in a national network of retail clinics, the prevalence of GAS positivity was 28 percent among those with ≥1 feature of viral illness [71]. The prevalence of GAS positivity decreased with increasing numbers of viral features. Among children with viral features, the prevalence of GAS positivity was greater than the prevalence of GAS carriage (i.e., the prevalence of GAS positivity in asymptomatic children), which ranged from 5 to 21 percent in a systematic review [11], suggesting that some of the children with viral features had acute GAS pharyngitis.
Choice of test — The diagnosis of GAS pharyngitis is supported by a positive throat culture, RADT, or molecular assay for GAS.
For children and adolescents in whom microbiologic testing for GAS is necessary, we suggest performance of a RADT. Standard throat culture and molecular assays are acceptable alternatives [72].
If initial testing with RADT is negative in a child or adolescent, we recommend follow-up testing with standard throat culture because RADT may miss as many as 30 percent of cases of GAS pharyngitis [39,60, 73-75]. Confirmation of negative RADT with throat culture is not necessary in adults. The risk of an initial episode of ARF in an adult with GAS pharyngitis is extremely low, even if an episode of streptococcal pharyngitis is untreated [39].
If initial testing with a molecular assay is negative, follow-up testing with a standard throat culture is not necessary, given the high sensitivity of molecular assays [76].
Preference for initial testing with RADT is based upon practical considerations. RADT are available in almost all practice settings, and the immediate results are appealing to patients, caregivers, and clinicians given the advantages of early diagnosis and treatment, including earlier clinical cure and return to school (for children) and work (for caregivers). Although immediate results also are available with molecular assays, use of molecular assays is limited by cost and complexity. Despite the practical considerations, initial testing with RADT may be less cost effective than initial testing with standard throat culture. Most children who require microbiologic testing for pharyngitis do not have GAS pharyngitis and will have a negative RADT. Given that negative RADT in children and adolescents must be confirmed with throat culture, if RADT is used as the initial test, the majority of children and adolescents who are tested will require both RADT and throat culture.
Specimen collection and processing — The key to optimizing detection of GAS in clinical specimens is appropriate collection and transport of the sample [75]:
●Specimens should be obtained before initiation of antimicrobial therapy because a single dose of antibiotics can result in a negative culture or RADT.
●If RADT is to be performed, it is suggested that the throat be swabbed with two swabs simultaneously [75]. One is used for RADT; if RADT is positive, the second swab can be discarded. If RADT is negative, the second swab can be used for standard culture.
●Specimens should be obtained by vigorous swabbing of both tonsils (or tonsillar fossae in patients who have undergone tonsillectomy) and the posterior pharynx. The swab(s) should be moved into and out of the mouth without touching the tongue or the buccal mucosa. The importance of obtaining an adequate specimen cannot be overstated; the sensitivity of both culture and RADT correlates with inoculum size [37,77,78].
Investigation in the Community
Throat swabs do not usually play a significant role in the management of sore throat, or the investigation of scarlet fever in the community – Strep A is a commensal, so its presence doesn’t necessarily mean that it is the cause of a sore throat, and the results aren’t back until some days after the decision on whether to treat has to be made [35,36]. The current guidance says that we should consider taking a throat swab where there is ‘diagnostic uncertainty’ or concerns about antibiotic resistance – presumably so that if first-line antibiotics don’t help, we have sensitivities to guide the second choice. However, in some areas swabbing may be arranged as part of public health investigations – this is in line with the Government’s advice on scarlet fever which says that we should consider swabbing if ‘a case is suspected to be part of an outbreak — the local health protection team should advise primary care if a local outbreak is suspected and when testing is appropriate’ [35,36].
Differential diagnosis
The differential diagnosis of GAS pharyngitis includes both infectious and non-infectious causes of pharyngitis.
Other infectious causes of pharyngitis — Acute infectious pharyngitis in children and adolescents is caused by a variety of agents. The frequency of these pathogens varies according to the age of the child, season, and geographic area.
Microbiologic testing may be necessary to differentiate GAS pharyngitis from other infectious causes of pharyngitis that require treatment or infection control and in children and adolescents whose symptoms worsen or persist for more than five to seven days (whether or not they were treated for GAS) [79].
Other bacterial infections
Other bacterial causes of pharyngitis that may require treatment are listed below. Although it is not necessary to exclude these infections in children with pharyngitis who test negative for GAS, microbiologic testing is warranted in children with compatible clinical or epidemiologic features.
● Group C and G streptococci – Group C and G streptococci have been reported to cause epidemic and sporadic pharyngitis in school-age children and adults, although there has been some controversy over their etiologic role [80-84]. Group C or G streptococci may be identified with standard throat culture, but most laboratories do not routinely identify them unless specifically requested to do so. Group C or group G streptococcal pharyngitis may warrant treatment if the patient remains symptomatic when the results of the culture are available. The diagnosis and treatment of group C and G streptococcal infections are discussed separately.
● Neisseria gonorrhoeae – N. gonorrhoeae is a relatively rare cause of pharyngitis but may occur in patients with oral-genital contact. Most cases are asymptomatic; when present, findings are nonspecific (e.g., pharyngeal erythema, oedema, or exudate). Evaluation for gonococcal pharyngitis with a nucleic acid amplification test or throat culture on media specific for N. gonorrhoeae may be warranted in patients with risk factors (e.g., unprotected oral-genital contact). If N. gonorrhoeae is detected, treatment is necessary to prevent transmission and disseminated disease [63].
● Fusobacterium necrophorum – F. necrophorum causes most cases of jugular vein suppurative thrombophlebitis (Lemierre syndrome). Lemierre syndrome predominantly affects previously healthy adolescents and young adults. Clinical features include high fever (>39°C [102.2°F]), rigors, respiratory symptoms, and unilateral neck swelling or pain, findings typically absent in GAS pharyngitis [63].
● A. haemolyticum – A. haemolyticum pharyngitis occurs predominantly in adolescents (85-87). Clinical features overlap with those of GAS and include fever, exudative pharyngitis, and rash on the extensor surfaces of the arms (86, 88). The rash occurs in approximately one-half of patients but, in contrast with the rash of scarlet fever, does not peel (85,86,88). A. haemolyticum grows slowly on sheep blood agar plates and produces a tiny zone of beta haemolysis after 48 to 72 hours. Detection is improved (larger colony size and wider zone of haemolysis) by culture on human or rabbit blood agar (89). In in vitro studies, A. haemolyticum was unresponsive to penicillin; erythromycin is the drug of choice (85).
● Diphtheria – Diphtheria is uncommon in developed countries but is important to consider in patients from endemic areas. In contrast with GAS pharyngitis, which has acute onset, the onset of symptoms in diphtheria is usually gradual, beginning with mild pharyngeal injection and erythema. The hallmark of diphtheria is the formation of a tightly adherent gray membrane in the nares and throat. This membrane occurs in at least one-third of patients and causes bleeding when it is dislodged [63].
● Tularaemia – Tularaemia is an uncommon cause of pharyngitis that should be considered in patients with pharyngitis unresponsive to penicillin. It is usually acquired by ingestion of poorly cooked wild animal meat or contaminated water. Clinical features of oropharyngeal tularaemia include fever, painful ulcerative-exudative pharyngitis, and cervical lymphadenitis [63].
● Mycoplasma pneumoniae – M. pneumoniae can cause pharyngitis and other respiratory tract illness in children ≥6 years. M. pneumoniae accounts for 5 to 16 percent of cases of pharyngitis; the wide range may be related to the cyclicity of M. pneumoniae epidemics [90,91].
Viral infections
Viruses are the most common cause of acute pharyngitis [92-94]. Clinical features suggestive of viral aetiology include concurrent conjunctivitis, rhinorrhoea, cough, hoarseness, anterior stomatitis, discrete ulcerative lesions, viral exanthems, and/or diarrhoea [39]. Most children and adolescents with negative microbiologic tests for GAS have viral pharyngitis, which is a self-limiting condition and can be treated symptomatically without additional testing.
Viral infections in the differential diagnosis of GAS pharyngitis in children and adolescents that have important management or infection control implications are listed below. Although it is not necessary to exclude these infections in children with pharyngitis who test negative for GAS, microbiologic testing may be warranted in children with compatible clinical or epidemiologic features.
●Infectious mononucleosis – Epstein-Barr virus (EBV) and cytomegalovirus account for most cases of infectious mononucleosis, a clinical syndrome that classically occurs in adolescents and is characterized by fever, severe pharyngitis (which lasts longer than pharyngitis due to GAS), and anterior and posterior cervical or diffuse lymphadenopathy, lymphocytosis, and increased aminotransferase levels [85-96]. Prominent constitutional symptoms include fatigue, anorexia, and weight loss. Examination findings may include periorbital or palpebral oedema, mild hepatomegaly, and splenomegaly. Patients who are treated with ampicillin, amoxicillin, or other antibiotics may develop a characteristic rash. Laboratory findings may include increased aminotransferases and predominance of atypical lymphocytes in the differential blood count.
Unlike adolescents, who typically present with classic symptoms, younger patients with EBV infection may have a more subtle presentation that can make diagnosis difficult.
Patients with infectious mononucleosis and splenomegaly require activity restriction to prevent splenic rupture.
●Primary HIV infection – Primary HIV infection may cause an acute retroviral syndrome (similar to infectious mononucleosis) in sexually active adolescents or rarely in children who have been sexually abused. The onset of symptoms usually occurs within days to weeks after the initial exposure. Clinical features of primary HIV infection include prominent cervical or generalized adenopathy and persistent constitutional complaints (e.g., fever, weight loss). Laboratory features may include lymphopenia and increased aminotransferase levels [92-94].
●Herpes simplex virus – Herpes simplex virus (HSV) pharyngitis should be considered in children and adolescents with the characteristic enanthem or ulcerative lip lesion. HSV is more common in adolescents than in younger children and is characterized by its severity and duration (frequently >7 days). HSV pharyngitis in children and adolescents may respond to acyclovir therapy [92-94].
●Influenza – Influenza infection is characterized by fever, cough, headache, and myalgias that occur in seasonal epidemics. Pharyngitis caused by influenza may be exudative. Influenza pharyngitis should be considered in children and adolescents with fever and severe illness (pharyngitis, cough, or both in the absence of another known cause of illness) during influenza season (regardless of influenza immunization status) [97]. Antiviral therapy is indicated for children at risk for complications or severe disease. Laboratory confirmation should not delay initiation of treatment [92-94].
●Severe acute respiratory syndrome coronavirus 2 – Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), may cause pharyngitis in children [92].
●Enteroviruses – Enteroviruses, specifically coxsackie A viruses, cause herpangina, which is characterized by small vesicles in the posterior pharynx. In one series of 50 children (aged 1 to 10 years) with acute pharyngitis, enterovirus polymerase chain reaction was positive in 8 percent [98].
●Adenovirus – Adenovirus may manifest as pharyngitis, tonsillitis, or pharyngoconjunctival fever. There are no distinguishing characteristics of infections caused by adenovirus except in patients with pharyngoconjunctival fever. The presence of exudate is common but not invariable [92].
When pharyngitis is part of a viral syndrome that causes nasopharyngitis, nasal congestion and discharge may be more prominent than sore throat. These infections generally resolve with symptomatic therapy, and it is not usually necessary to identify the specific viral pathogen
Viruses that cause nasopharyngitis include [92-04]:
●Rhinoviruses
●Coronaviruses, including SARS-CoV-2, which causes COVID-19
●Respiratory syncytial virus
●Parainfluenza viruses
Non-infectious causes of pharyngitis — Non-infectious causes of sore throat include irritation or drying of the pharynx (often from mouth-breathing overnight secondary to nasal obstruction from viral infection or allergic inflammation), foreign body (e.g., fish bone), chemical exposure, referred pain from extrapharyngeal sources (e.g., dental abscess, otitis media). These can usually be differentiated from infectious pharyngitis through information from the history or physical examination [63].
Decision making tools in the Community
For those who have a sore throat or tonsillitis, but no signs of scarlet fever, and who are not so ill that you feel they need hospital review (using the tools already mentioned if needed to aid that judgment), the decision has to be made as to whether they need antibiotics. The NICE guidance on sore throat recommends two decision making tools – Centor and FeverPAIN [99] but the interim clinical guidance summary produced by NHSE, the UKHSA, the RCGP, the RCPCH, the Royal Pharmaceutical Society and NICE seems to focus on FeverPAIN because it is validated in primary care and suggests that we adjust our threshold for antibiotic prescribing to prescribe for those with a FeverPAIN score of 3 or more [48].
FeverPAIN/Centor criteria [99]
FeverPAIN criteria
• Fever (during previous 24 hours)
• Purulence (pus on tonsils)
• Attend rapidly (within 3 days after onset of symptoms)
• Severely Inflamed tonsils
• No cough or coryza (inflammation of mucus membranes in the nose)
Each of the FeverPAIN criteria score 1 point (maximum score of 5). Higher scores suggest more severe symptoms and likely bacterial (streptococcal) cause. A score of 0 or 1 is thought to be associated with a 13 to 18% likelihood of isolating streptococcus. A score of 2 or 3 is thought to be associated with a 34 to 40% likelihood of isolating streptococcus. A score of 4 or 5 is thought to be associated with a 62 to 65% likelihood of isolating streptococcus.
Centor criteria
• Tonsillar exudate
• Tender anterior cervical lymphadenopathy or lymphadenitis
• History of fever (over 38 degrees Celsius)
• Absence of cough
Each of the Centor criteria score 1 point (maximum score of 4). A score of 0, 1 or 2 is thought to be associated with a 3 to 17% likelihood of isolating streptococcus. A score of 3 or 4 is thought to be associated with a 32 to 56% likelihood of isolating streptococcus.
This is a significant lowering of the threshold as the NICE guidance on sore throats usually advises only that we consider an immediate or back-up antibiotics with a FeverPAIN score of 4 or 5 and that we consider a back-up antibiotic or no antibiotic with a score of 2 or 3. In normal times, a FeverPAIN score of 2-3 is associated with a 34-40% likelihood of isolating streptococcus and a score of 4-5 is associated with a 62 – 65% chance, however increased incidence may mean that these predictive values are increased at the current time. The FeverPAIN score has been criticised for giving one point for those who attend within three days of the onset of symptoms. This is presumably meant to indicate severity of symptoms, however in an environment of public panic and the trend towards wanting immediate access to a doctor for all respiratory symptoms, it is arguable whether attending quickly is actually a marker of severity.
Treatment:
Goals of treatment — The goal of antibiotic therapy for streptococcal pharyngitis is multifold and includes:
●Reducing symptom severity and duration
●Prevention of acute complications, such as otitis media, peritonsillar abscesses, or other invasive infections
●Prevention of delayed complications or immune sequelae, particularly acute rheumatic fever
●Prevention of spread to others
Symptom reduction — Antibiotic treatment has been shown to reduce symptom severity and hasten the rate of recovery in patients with streptococcal pharyngitis [100,101]. However, even without antibiotic therapy, symptoms typically resolve in about three to five days for most patients [102] making the prevention of complications a key goal of care.
Prevention of complications — Complications of streptococcal pharyngitis can result from extension of infection beyond the oropharynx, termed suppurative complications, or as immune phenomena, termed nonsuppurative complications.
Suppurative complications
Rates of otitis media and peritonsillar abscesses are each reduced with antibiotic use. In a large meta-analysis of randomized trials comparing antibiotics to placebo in adults and children with streptococcal pharyngitis, antibiotics reduced the incidence of acute otitis media within 14 days (0.47 versus 2.0 percent; risk ratio [RR] 0.30, 95% CI 0.15-0.58) and peritonsillar abscess at two months (0.24 versus 2.3 percent; RR 0.15, 95% CI 0.05-0.47) [100]. Reduction in the rates of acute sinusitis were also observed but did not reach statistical significance. The effect on less common but severe suppurative complications including bacteraemia and necrotizing fasciitis has not been studied, though it is reasonable to surmise that antibiotics would have a protective effect.
Nonsuppurative complications
Acute rheumatic fever — The prevention of acute rheumatic fever is one of the main indications for antibiotic treatment of streptococcal pharyngitis. Acute rheumatic fever and rheumatic heart disease are important causes of cardiovascular death worldwide [103,104]. In a meta-analysis of 14 randomized trials comparing penicillin with placebo in over 8000 adults and children with sore throat, penicillin decreased the risk of rheumatic fever by about two-thirds [100]. The absolute risk reduction is likely highest in children aged 5 to 15 residing in developing nations, where incidence of rheumatic fever peaks [104,105].
Other nonsuppurative complications — Data on the benefits of antibiotics in preventing other nonsuppurative complications are limited. Antibiotics probably prevent poststreptococcal glomerulonephritis based on a meta-analysis of 10 randomized trials comparing antibiotics with placebo in adults and children with sore throat, though there were too few cases in these trials to conclude this with certainty [100]. The effect of antibiotics on other nonsuppurative complications such as poststreptococcal arthritis and paediatric autoimmune neuropsychiatric disorder associated with group A streptococci (PANDAS) is not well studied.
Prevention of transmission — GAS can spread among close contacts, leading to clusters of cases and recurrent infections in households or other close-contact settings. The rate of GAS transmission from an infectious case to close contacts is estimated to be between 5 and 50 percent [106-108]. Although no studies have directly evaluated the effect of antibiotic treatment on transmission, antibiotic use appears to eliminate GAS from the oropharynx in about 80 to 90 percent of cases after 24 hours of therapy [109,110]. When untreated, historic epidemiologic data suggest approximately 50 percent of patients with streptococcal pharyngitis will continue to harbour GAS in the oropharynx three to four weeks after symptom onset [39,102].
WHOM TO TREAT — Antibiotic treatment is recommended for any patient with symptomatic pharyngitis or tonsillopharyngitis who has a positive rapid antigen test or culture for group A Streptococcus (GAS).
Empiric treatment is generally not recommended, as the clinical features of GAS pharyngitis and non-streptococcal pharyngitis broadly overlap [111-112]. Short delays in therapy (e.g., while awaiting culture results) have not been associated with increased rates of complications such as acute rheumatic fever [39]. However, whether such delays effect rates of other complications (e.g., development of peritonsillar abscess) is not known. If clinical suspicion for GAS pharyngitis is high and testing results cannot be obtained rapidly, it is reasonable to start antibiotic treatment while test results are pending [113]. If testing does not confirm the diagnosis, antibiotics should be discontinued.
Antibiotic treatment is not recommended for asymptomatic chronic GAS carriers or for GAS carriers who have superimposed viral infections [111, 112,114].
Treatment of initial episodes
Antibiotic treatment is the mainstay of care.
Supportive care measures such as nonsteroidal anti-inflammatory drugs (NSAIDs) or acetaminophen may be administered to relieve fever and pain.
Antibiotic treatment — The antibiotic treatment recommendations presented below are largely consistent with recommendations from the NICE Guidelines, Infectious Diseases Society of America, the American Heart Association, and the American Academy of Paediatrics [97, 111,114-116]. Guidelines from other regions vary [117-119].
Penicillin — Penicillin is the treatment of choice for group A Streptococcus (GAS) pharyngitis due to its efficacy, safety, narrow spectrum, and low cost. Resistance to penicillin among clinical GAS isolates has not been documented. Penicillin is the only antibiotic that has been studied and shown to reduce rates of acute rheumatic fever [100].
●For most adult patients, we use oral penicillin V 500 mg two to three times daily for 10 days. Oral amoxicillin is also a reasonable option [1, 43, 99].
●For most children, we use either oral penicillin V or amoxicillin. Amoxicillin is often preferred for young children because the taste of the amoxicillin suspension is more palatable than that of penicillin. Amoxicillin can also be given once daily, either immediate release or as an extended-release tablet. In several randomized trials, standard-dose and once-daily dosing of amoxicillin appeared to have equivalent efficacy as oral penicillin [120-124].
●For patients with a history of acute rheumatic fever (who are not receiving antibiotic prophylaxis), options include oral penicillin, oral amoxicillin, or single-dose intramuscular (IM) benzathine penicillin. Because adherence is critical for patients with a history of acute rheumatic fever, choice is based on patient values and preferences. While IM benzathine penicillin can be given as a single dose, the drug is expensive in some regions, frequently unavailable, and causes injection site pain. In contrast, oral options are readily available but carry the risk of incomplete adherence [1].
The duration of therapy for oral penicillin or amoxicillin is 10 days. Although symptoms typically improve within the first few days of treatment [102,125,126), treating for 10 days appears to enhance the rate of GAS eradication from the oropharynx when compared with 5 or 7 days [5, 99,111,127-129]. Because complications, particularly immune sequelae, are likely related to the presence of GAS in oropharynx and can be severe, treating with a 10-day course seems prudent.
IM penicillin appears to be more effective than oral penicillin at eradication of GAS from the oropharynx [130] and has been most well studied for the prevention of acute rheumatic fever [100]. However, as noted above, IM penicillin is expensive in some regions and not always available. Thus, for patients with a history of acute rheumatic fever (who are high risk for cardiac complications compared with those without this history), we discuss the risk and benefits of its use on an individual basis [131].
Alternatives to penicillin — Cephalosporins, clindamycin, and macrolides are alternatives for patients who are allergic to penicillin or who cannot otherwise tolerate penicillin. Dosing and duration of therapy should be based on age and type of medication, usually between 5 to 10 days. Selection of an agent depends on the type of allergy, local antibiotic resistance rates, and patient values and preferences [39,132, 133].
The approach to antibiotic selection for patients with penicillin allergy varies among experts:
●For patients with mild, non-IgE-mediated reactions to penicillin (eg, maculopapular rash beginning days into therapy), generally a first-generation cephalosporin such as cephalexin is preferred because of its narrow spectrum and the low likelihood of cross-reactivity [1].
For patients with mild, possibly IgE-mediated reactions (eg, urticaria or angioedema but not anaphylaxis), a second- or third-generation cephalosporin with a side chain that is dissimilar to penicillin, such as cefuroxime, cefdinir, or cefpodoxime is recommended [1].
When using an oral cephalosporin, treatment is generally for 10 days. A 5-day treatment course with cefdinir or cefpodoxime is also acceptable. These shorter treatment courses are US Food and Drug Administration approved and, in randomized trials, had similar clinical and microbiologic efficacy as 10-day courses of oral penicillin [134-137].
●For patients with a history of severe angioedema and/or anaphylaxis or with serious delayed reactions or for patients who cannot take cephalosporins, a macrolide, such as azithromycin is generally used. A major advantage of azithromycin is that it can be given for a three- or five-day course due to its extended half-life [138].
A key consideration when using a macrolide is potential drug resistance. Macrolide resistance rates are growing and vary with geography [139-144]. Generally, higher macrolide resistance rates have been observed in Asia and Europe when compared with the United States. Clinicians should take into account local resistance patterns or consult local antibiograms when prescribing macrolides, if possible.
●For patients with known or suspected macrolide-resistant GAS who cannot tolerate cephalosporins, treat with a 10-day course of clindamycin.
The above approach is generally consistent with recommendations from both the American Academy of Paediatrics and the Infectious Diseases Society of America [39,116].
Other experts prefer to perform a test-dose procedure before prescribing cephalosporins to patients with penicillin allergies. Because this is generally not feasible in the outpatient clinic, a more conservative approach to treatment is an option for patients with mild, non-IgE-mediated reactions or IgE-mediated reactions [1]:
●For patients with mild, non-IgE-mediated reactions, a third-generation cephalosporin, such as cefpodoxime or cefdinir, is selected.
●For patients with any possible IgE-mediated reactions (including anaphylaxis), an alternative to cephalosporins such as a macrolide or clindamycin is selected.
Broad use of cephalosporins may promote antimicrobial resistance and are generally more costly than penicillins. No trial has evaluated the use of alternatives to penicillin for the prevention of acute rheumatic fever; thus, penicillin remains the treatment of choice when feasible [1].
Tetracyclines, sulphonamides, and fluoroquinolones should not be used for treatment of streptococcal pharyngitis due to the high prevalence of resistance [139-144], potential for clinical failure, and/or high side-effect profile [145].
Adjunctive treatment — We offer supportive care (rest, adequate fluid intake, avoidance of respiratory irritants, soft diet) to all patients and systemic agents such as NSAIDs or acetaminophen for patients who desire medication for fever or pain control. We avoid using systemic glucocorticoids for symptom relief because antibiotics and systemic analgesics are generally effective, and the addition of systemic glucocorticoids increases the likelihood of adverse events [1].
Response to therapy
Resolution of symptoms — Fever and constitutional symptoms typically resolve within one to three days of starting treatment [102,146-150]. Follow-up visits are not needed for most patients.
Most patients can return to work or school after completing one full day of treatment, provided they are afebrile and otherwise well. This recommendation is based on a small cohort study in children that showed that about 80 percent of patients with culture-proven group A streptococcal (GAS) pharyngitis clear the organism from the oropharynx within 24 hours of starting therapy [109]. A second cohort study evaluating 111 children with pharyngitis and a positive rapid antigen detection test (RADT) showed that 91 percent of patients treated with amoxicillin by 5:00 PM on the day of therapy had negative follow-up RADTs the following morning [110].
Indications for test of cure — For patients who are asymptomatic at the end of a course of antibiotic therapy, a test of cure is typically not needed [151]. We generally perform a test of cure (culture or RADT) in the following patients, who are at risk for complications, recurrent infection, or spreading infection to others:
●Patients with a history of acute rheumatic fever
●Patients who acquired infection during an outbreak of acute rheumatic fever or poststreptococcal glomerulonephritis
●Patients who acquired infection during a cluster of cases in their household or other close-contact setting
For patients who test positive in these circumstances, we repeat a full 10-day course of therapy. Usually, an antibiotic that has greater beta-lactamase stability than the one used for the initial treatment course should be selected. As examples, if penicillin was used for initial treatment, we use either amoxicillin-clavulanate or a first-generation cephalosporin; if a first-generation cephalosporin was used, we select a later-generation cephalosporin. The rationale for this strategy is based on clinical data that suggest relapse rates may be lower with cephalosporin use, as well as scientific observations that antibiotics with greater beta-lactamase activity may be more effective in eradicating GAS from the oropharynx [1].
Patients who are asymptomatic following an appropriate course of therapy who test positive but lacked an appropriate indication for a test of cure are not usually treated. The patients are likely chronic carriers.
Persistent or recurrent symptoms
Evaluation — For patients who have persistent or recurrent symptoms consistent with GAS pharyngitis after completing a course of antibiotic therapy, we generally repeat testing for GAS. Because chronic GAS carriage can occur after antibiotic therapy [4-11], we generally avoid testing in patients whose symptoms are highly consistent with viral pharyngitis (e.g., sore throat accompanied by cough, conjunctivitis, or rhinorrhoea) or other aetiology. For patients with persistent or recurrent symptoms consistent with GAS pharyngitis, a positive test result should raise suspicion for any of the following:
●Nonadherence with the prescribed antimicrobial regimen
●Recurrent infection, which refers to new infection with the initial infecting strain or a new strain
●Persistent infection, also termed treatment failure
●Infection with a different pathogen superimposed on chronic GAS carriage
●Presence of a suppurative complication, such as a peritonsillar abscess
Distinguishing among these states is typically based on epidemiologic and clinical history, which can be challenging as symptoms overlap and GAS testing can be positive in all.
-Suspicion for recurrent infection should be raised when clusters of GAS infections are occurring within the patient's household, school, workplace, or other close-contact setting. Symptoms associated with recurrent infection with the same serotype may be milder than with the initial infection [152]. Persistent infection is rare but most often occurs in children, particularly those under age 5 [153]. Initial antibiotic choice may also influence the likelihood of recurrent or persistent infection. Selection of an antibiotic to which there is potential GAS resistance, such as a macrolide or clindamycin, increases the likelihood of treatment failure. Additionally, some studies suggest that cephalosporins may be more effective than penicillin for preventing relapse [154].
-The presence of persistent or recurrent symptoms should also raise suspicion for an alternate initial diagnosis or new infection with a different pathogen in a chronic GAS carrier. For patients with repeated episodes of pharyngitis, culturing for GAS when patients are between episodes may help distinguish chronic carriage from active infection. A positive culture in an asymptomatic patient suggests that the patient is a carrier and that symptoms are due to an alternate cause as outlined in differential diagnosis section [1].
A persistent, severe sore throat accompanied by fever, trismus, or a muffled voice suggests a local complication such as peritonsillar cellulitis or abscess.
Antibiotic treatment — We generally repeat a 10-day course of antibiotic treatment for patients with persistent or recurrent streptococcal pharyngitis. The selection of an antibiotic varies based on patient history.
●For patients who were nonadherent to the initial antibiotic regimen, typically they can be treated with intramuscular penicillin. Injections of penicillin G benzathine provide bactericidal levels against GAS for 21 to 28 days. For those who are allergic or who cannot otherwise tolerate penicillin, antibiotic selection should be based on the patient's preferences and reasons for nonadherence [1].
●For patients with persistent infection or an initial recurrence, we usually select an antibiotic that has greater beta-lactamase stability than the one used for the initial treatment course. As examples, if penicillin was used for initial treatment, we use either amoxicillin-clavulanate or a first-generation cephalosporin; if a first-generation cephalosporin was used, we select a later-generation cephalosporin [1].
The approach is based on a meta-analysis of four randomized trials evaluating over 1300 adults and children with GAS pharyngitis that showed decreased clinical relapse rates when comparing cephalosporins with penicillins (25 versus 46 percent; odds ratio 0.55, 95% CI 0.30-0.99) [155]. Additional studies suggest that bacteriologic cure rates may be higher for cephalosporins compared with penicillin [156-159]. Scientific observations also support the selection of antibiotics with beta-lactamase stability when treating persistent or recurrent GAS infection [160-162]. Some bacteria that colonize the oropharynx, such as Staphylococcus aureus, Haemophilus influenza, and Moraxella catarrhalis, produce beta-lactamases that inactivate penicillin, leading to decreased activity of penicillin against GAS [163-185]. Penicillin also decreases the quantity of alpha-streptococci in the oropharynx, which naturally protect against GAS infection [166-168]. Cumulatively, these effects may inadvertently promote the survival and persistence of GAS in the oropharynx. By contrast, antibiotics with beta-lactamase activity may have a more balanced effect on the oropharyngeal flora, resulting in greater likelihood of GAS eradication.
A small number of patients experience multiple recurrences, which may be related to the infecting GAS strain [169-171], host immune response [147,172], or other factors that are not yet well characterized.
●For patients with multiple recurrences of GAS pharyngitis, treatment should be with an antibiotic from a class that has not been used previously, such as clindamycin.
●For patients with frequent, mild to moderate recurrent infections, delaying the start of antibiotic therapy by two to three days is an alternate approach. This approach is derived from observational data that suggest delaying therapy may allow the development of immunity against the infecting strain, resulting in higher eradication rates [147,153,172] without increasing the risk of acute rheumatic fever [173,174]. This approach is generally avoided in patients with severe symptoms or when GAS is actively circulating in the community, as it prolongs symptom duration and may increase the risk of suppurative complications and/or transmission of GAS to others.
●For patients with frequent, severe episodes of GAS pharyngitis that recur despite appropriate antibiotic treatment, tonsillectomy should be considered.
It is not necessary to perform follow-up testing for persistent or recurrent infection unless the patient becomes symptomatic after antibiotic treatment or special circumstances as outlined above are present.
When recurrent infections are thought to be due to ongoing GAS circulation among household members, consider testing all household members and treating those who test positive. When recurrent infections are thought to be due to ongoing GAS circulation in other close-contact settings such as day care centres or workplaces, determine the best management approach on a case-by-case basis.
Tonsillectomy — Tonsillectomy is rarely indicated for patients with recurrent GAS pharyngitis. The need for tonsillectomy should be determined in each individual case based on the patient age, the frequency and severity of infections, history of antibiotic use, and patient values and preferences [1,39].
Prevention
General prevention
Hand hygiene — Hand hygiene is a key measure for preventing spread to others, especially after coughing or sneezing and before preparing foods or eating, and we remind all patients of its importance.
Postexposure prophylaxis — Testing and treatment of asymptomatic persons who have been exposed to a patient with group A Streptococcus (GAS) pharyngitis are not routinely recommended [30], except for patients with a history of acute rheumatic fever, during outbreaks of acute rheumatic fever and/or poststreptococcal glomerulonephritis, or when GAS infections are recurring in households or other close-contact settings.
Special populations
Patients with a history of acute rheumatic fever — Patients with a history of acute rheumatic fever are at high risk for recurrent rheumatic fever and the development of chronic valvular heart disease with any subsequent GAS infection. We educate these patients on the risk of recurrence and its complications and recommend long-term antibiotic prophylaxis. Antibiotic selection and duration of therapy vary based on patient characteristics and medication availability.
Chronic carriers have GAS in their pharynx but are asymptomatic and have little or no immunologic response to the organism. Carriers are unlikely to spread GAS to their close contacts and are at very low, if any, risk for developing suppurative or nonsuppurative complications [150,174,175-178]. Treatment is generally not recommended for the carrier state (39), although it may be considered for close contacts in scenarios such as invasive disease outbreaks [178]. Tonsillectomy is not recommended solely for the purpose of reducing GAS pharyngitis [39]
However, we do consider treating carriers during outbreaks of acute rheumatic fever and/or poststreptococcal glomerulonephritis or when GAS infections are recurring in households or other close-contact settings [178-179].
Oral options for treatment of chronic carriage include clindamycin, amoxicillin-clavulanate, and penicillin plus rifampin; the duration of treatment is usually 10 days [39]. When used with either oral or parenteral penicillin, rifampin is typically given only during the last four days of therapy [39].
Prevention of foodborne illness — Streptococcal contamination of food has been implicated in foodborne outbreaks of pharyngitis [180-184], and foodborne transmission of GAS pharyngitis by asymptomatic food service workers with nasopharyngeal carriage has been reported [183,185,186]. Factors that can reduce foodborne transmission of GAS pharyngitis include thorough cooking, complete reheating, and use of gloves while handling food [180,187].
Vaccination — No vaccine against GAS is available for clinical use. However, research on GAS vaccine development is ongoing [188-192]. An important area of uncertainty is whether vaccine-induced antibodies may cross-react with host tissue to produce nonsuppurative sequelae in the absence of clinical infection.
Isolation Parents may ask us whether their children with scarlet fever or a sore throat should isolate or stay off school – there have been no changes in the law or new rules issued, as happened during the pandemic, recent guidance advises that a person is infectious for 2-3 weeks if antibiotics are not used, but that exclusion from school or nursery need only be for 24 hours after starting antibiotics [193].
Prognosis — GAS bacteraemia remains a serious infection. The estimated mortality rate associated with invasive GAS infections in children ranges from 2 to 8 percent [194-201]. Long-term disability occurs in an additional 3 to 8 percent of children following invasive GAS infection [194, 198].
Early recognition of potential GAS infections is essential, as survival depends on rapid initiation of appropriate treatment. Antibiotics, surgery, and probably intravenous administration of human immunoglobulins are all indicated in cases of severe infection. In spite of modern therapy, the death rate remains high, and new therapeutic alternatives have to be found in order to reduce this rate.
Streptococci are ubiquitous, and their significance in medicine is remarkable. Exciting advances are being made in the diagnosis and in the understanding of the mechanisms of the pathogenesis of Streptococcus infections, as well as in control of these well-known organisms. Problems with antibiotic resistance must preclude complacency in dealing with these common pathogens.
Nil
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.
The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.
Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, I hope this message finds you well. I want to express my utmost gratitude for your excellent work and for the dedication and speed in the publication process of my article titled "Navigating Innovation: Qualitative Insights on Using Technology for Health Education in Acute Coronary Syndrome Patients." I am very satisfied with the peer review process, the support from the editorial office, and the quality of the journal. I hope we can maintain our scientific relationship in the long term.
Dear Monica Gissare, - Editorial Coordinator of Nutrition and Food Processing. ¨My testimony with you is truly professional, with a positive response regarding the follow-up of the article and its review, you took into account my qualities and the importance of the topic¨.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, The review process for the article “The Handling of Anti-aggregants and Anticoagulants in the Oncologic Heart Patient Submitted to Surgery” was extremely rigorous and detailed. From the initial submission to the final acceptance, the editorial team at the “Journal of Clinical Cardiology and Cardiovascular Interventions” demonstrated a high level of professionalism and dedication. The reviewers provided constructive and detailed feedback, which was essential for improving the quality of our work. Communication was always clear and efficient, ensuring that all our questions were promptly addressed. The quality of the “Journal of Clinical Cardiology and Cardiovascular Interventions” is undeniable. It is a peer-reviewed, open-access publication dedicated exclusively to disseminating high-quality research in the field of clinical cardiology and cardiovascular interventions. The journal's impact factor is currently under evaluation, and it is indexed in reputable databases, which further reinforces its credibility and relevance in the scientific field. I highly recommend this journal to researchers looking for a reputable platform to publish their studies.
Dear Editorial Coordinator of the Journal of Nutrition and Food Processing! "I would like to thank the Journal of Nutrition and Food Processing for including and publishing my article. The peer review process was very quick, movement and precise. The Editorial Board has done an extremely conscientious job with much help, valuable comments and advices. I find the journal very valuable from a professional point of view, thank you very much for allowing me to be part of it and I would like to participate in the future!”
Dealing with The Journal of Neurology and Neurological Surgery was very smooth and comprehensive. The office staff took time to address my needs and the response from editors and the office was prompt and fair. I certainly hope to publish with this journal again.Their professionalism is apparent and more than satisfactory. Susan Weiner
My Testimonial Covering as fellowing: Lin-Show Chin. The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews.
My experience publishing in Psychology and Mental Health Care was exceptional. The peer review process was rigorous and constructive, with reviewers providing valuable insights that helped enhance the quality of our work. The editorial team was highly supportive and responsive, making the submission process smooth and efficient. The journal's commitment to high standards and academic rigor makes it a respected platform for quality research. I am grateful for the opportunity to publish in such a reputable journal.
My experience publishing in International Journal of Clinical Case Reports and Reviews was exceptional. I Come forth to Provide a Testimonial Covering the Peer Review Process and the editorial office for the Professional and Impartial Evaluation of the Manuscript.
